Empagliflozin + Sitagliptin
Information about Empagliflozin + Sitagliptin
Empagliflozin + Sitagliptin Uses
Empagliflozin+Sitagliptin is used in the treatment of type 2 diabetes mellitus.
How Empagliflozin + Sitagliptin works
Empagliflozin + Sitagliptin is a combination of two medicines, empagliflozin and sitagliptin, which help control blood sugar levels in people with type 2 diabetes. Empagliflozin works by helping the kidneys remove extra sugar from the body through urine. Sitagliptin helps the body release more insulin when blood sugar is high and reduces the amount of sugar made by the liver. By working in different ways, these two medicines complement each other and provide better blood sugar control than either medicine alone.
Common side effects of Empagliflozin + Sitagliptin
Urinary tract infection, Fungal infection, Upper respiratory tract infection, Headache
Available Medicine for Empagliflozin + Sitagliptin
Alsita-EAlkem Laboratories Ltd
₹159 to ₹1692 variant(s)
Empajoy-SMacleods Pharmaceuticals Pvt Ltd
₹106 to ₹1292 variant(s)
Empazio STorrent Pharmaceuticals Ltd.
₹198 to ₹2202 variant(s)
Empasov SCipla Ltd
₹189 to ₹2092 variant(s)
Empaglyn SZydus Healthcare Limited
₹160 to ₹2102 variant(s)
Empha-SIntas Pharmaceuticals Ltd
₹199 to ₹2092 variant(s)
Glura EEris Lifesciences Limited
₹170 to ₹1802 variant(s)
Empatrol-SAristo Pharmaceuticals Pvt Ltd
₹1851 variant(s)
Empagreat-SMankind Pharma Ltd
₹109 to ₹1352 variant(s)
Empanorm DuoAlkem Laboratories Ltd
₹159 to ₹1692 variant(s)
Expert advice for Empagliflozin + Sitagliptin
- Let your doctor know if you are taking any other diabetes medicines with Empagliflozin + Sitagliptin, especially insulin or sulfonylureas, to avoid the risk of hypoglycemia (low blood sugar).
- Do not stop taking Empagliflozin + Sitagliptin suddenly without consulting your doctor, even if you feel well or your blood sugar improves.
- If you plan to undergo surgery or any major procedure, inform your doctor in advance, as temporary discontinuation may be advised.
- Empagliflozin + Sitagliptin is not suitable for people with type 1 diabetes or the treatment of diabetic ketoacidosis.